News coverage about Diffusion Pharmaceuticals (NASDAQ:DFFN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Diffusion Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.7897373236978 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Diffusion Pharmaceuticals traded down $0.03, hitting $0.52, during midday trading on Friday, Marketbeat reports. 174,998 shares of the stock were exchanged, compared to its average volume of 250,019. The company has a market capitalization of $27.28 million, a PE ratio of -0.45 and a beta of -1.06. Diffusion Pharmaceuticals has a twelve month low of $0.42 and a twelve month high of $3.04.
Get Diffusion Pharmaceuticals alerts:
Diffusion Pharmaceuticals (NASDAQ:DFFN) last released its quarterly earnings results on Thursday, May 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.22). equities analysts forecast that Diffusion Pharmaceuticals will post -0.44 EPS for the current year.
Several research analysts have recently issued reports on the company. ValuEngine raised Diffusion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. HC Wainwright set a $1.00 price target on Diffusion Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 16th.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.